Inst. for Cardiovascular and Metabolic Research (ICMR), School of Biological Sciences, Univ. of Reading, Reading, RG6 6UB Berkshire, U.K.
J Food Sci. 2013 Dec;78(12):N1921-8. doi: 10.1111/1750-3841.12293.
Epidemiological and clinical trials reveal compelling evidence for the ability of dietary flavonoids to lower cardiovascular disease risk. The mechanisms of action of these polyphenolic compounds are diverse, and of particular interest is their ability to function as protein and lipid kinase inhibitors. We have previously described structure-activity studies that reinforce the possibility for using flavonoid structures as templates for drug design. In the present study, we aim to begin constructing rational screening strategies for exploiting these compounds as templates for the design of clinically relevant, antiplatelet agents. We used the platelet as a model system to dissect the structural influence of flavonoids, stilbenes, anthocyanidins, and phenolic acids on inhibition of cell signaling and function. Functional groups identified as relevant for potent inhibition of platelet function included at least 2 benzene rings, a hydroxylated B ring, a planar C ring, a C ring ketone group, and a C-2 positioned B ring. Hydroxylation of the B ring with either a catechol group or a single C-4' hydroxyl may be required for efficient inhibition of collagen-stimulated tyrosine phosphorylated proteins of 125 to 130 kDa, but may not be necessary for that of phosphotyrosine proteins at approximately 29 kDa. The removal of the C ring C-3 hydroxyl together with a hydroxylated B ring (apigenin) may confer selectivity for 37 to 38 kDa phosphotyrosine proteins. We conclude that this study may form the basis for construction of maps of flavonoid inhibitory activity on kinase targets that may allow a multitargeted therapeutic approach with analogue counterparts and parent compounds.
流行病学和临床试验有力地证明了膳食类黄酮降低心血管疾病风险的能力。这些多酚化合物的作用机制多种多样,特别引人关注的是它们作为蛋白和脂激酶抑制剂的功能。我们之前描述过的结构活性研究,强化了使用类黄酮结构作为药物设计模板的可能性。在本研究中,我们旨在构建合理的筛选策略,以利用这些化合物作为模板来设计具有临床相关性的抗血小板药物。我们使用血小板作为模型系统,来剖析类黄酮、芪类、花色苷和酚酸对细胞信号和功能抑制的结构影响。确定为有效抑制血小板功能的相关功能基团至少包括两个苯环、一个羟基化的 B 环、一个平面 C 环、一个 C 环酮基和一个 C-2 位 B 环。B 环的邻苯二酚基团或单 C-4'羟基的羟基化可能是抑制胶原刺激的 125 至 130 kDa 酪氨酸磷酸化蛋白所必需的,但对于约 29 kDa 的磷酸酪氨酸蛋白可能不是必需的。C 环 C-3 羟基的去除以及 B 环的羟基化(芹菜素)可能赋予对 37 至 38 kDa 磷酸酪氨酸蛋白的选择性。我们得出结论,这项研究可能为构建类黄酮对激酶靶标的抑制活性图谱奠定基础,这可能允许使用类似物和母体化合物进行多靶点治疗方法。